Viatris (VTRS): 1 Stock the Doctor Ordered

This past week we saw a violent sell off in many of the leading tech names. That makes sense given the tremendous run they enjoyed in April and May. 

Now is a time for new stocks to lead the charge. They still need growth to attract investor attention. Just need a greater eye towards value. 

Enter Viatris (VTRS) as my Stock of the Week selection. 

Let me share their story by first winding the clock back a few years ago to how it got started. We are talking about the 2020 merger of a generic drug leader in Mylan with Pfizers Upjohn division. 

It is fair to say it was a hot mess out of the gate. Not just the difficulty in blending the companies together, but also buried under a mountain of debt. 

By 2024 and 2025 they were starting to turn the corner which included paying down nearly $4 billion in debt. 

Now the turnaround is fully unfolding leading to serious earnings growth and a doubling of shares this past year. Gladly there is plenty more upside likely in the years ahead.

Part of that upside should unfold as they are finally poised for growth. That shows up prominently in the average Wall Street earnings forecasts calling for 18-20% annual increase over the next five years.  

The other part of that ample upside comes from it still being extremely undervalued. Here we are only talking about a forward PE of 6.5 when the average large cap is trading for a PE of 20. 

As with all my picks it sparkles in the light of the Zen Ratings in the top 1% of all stocks analyzed. 

Top 18% Sentiment

Top 17% Momentum

Top 12% Value

Top 10% Safety

Top 3% Growth

That is a well rounded fundamental profile that points to more good times ahead for these shares. 

No...I don’t expect this one will get your heart racing like some of my other Stock of the Week selections. But in constructing a diversified portfolio of stocks it is wise to have solid anchors like VTRS in place.

In this case that anchor still has strong growth…still has AMPLE value…and if that was not enough how about a 3% dividend yield on top. 

This make up has the looks of another double over the next 18-24 months. Maybe not so boring after all. 

What To Do Next?

Viatris (VTRS) is just one of 20 stellar stocks found in my Zen Investor portfolio.

And that portfolio is up +30.34% so far in 2026. 

How is that possible? 

Investors still want growth…but now have a greater eye towards value.  

EXACTLY what the Zen Ratings model focuses on. 

EXACTLY what I have been doing as an investor over the last 40 years.  

To learn more about my unique investment process…and how to get access to my current top 20 stocks…just click the link below: 

Discover Zen Investor & Top 20 Stocks Now > 

Wishing you a world of investment success!

Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)

Editor of the Zen Investor

Want to get in touch? Email us at news@wallstreetzen.com.